Health
Boehringer’s Obesity Drug Faces Scrutiny
New data from STAT+ suggests that Boehringer Ingelheim's obesity drug is less effective at overall weight loss, despite showing promise in reducing liver fat. This could impact the company's competitiveness.
Coverage timeline — 1 article
STAT News
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
2026-06-07 18:30 UTC